HS-10296 hydrochloride salt form · hydrochloride · Parent HS-10296

Almonertinib hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor.

For research use only. Not for human or veterinary use.

Target EGFR

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

HS-10296 hydrochloride structure

CAS No.: 2134096-03-8

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
250 mg	USD 480.00	BP-02147C-250mg	In stock	Get quote
500 mg	USD 750.00	BP-02147C-500mg	In stock	Get quote
1 g	USD 1,220.00	BP-02147C-1g	In stock	Get quote
2 g	USD 1,950.00	BP-02147C-2g	In stock	Get quote
3 g	USD 2,350.00	BP-02147C-3g	In stock	Get quote
5 g	USD 3,120.00	BP-02147C-5g	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Related forms

Description

Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib hydrochloride is used for the research of the non-small cell lung cancer[1][2].

Biological activity

In Vitro Almonertinib (HS-10296) is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity, which canbe used to treat NSCLC[2]. Additionaly, Almonertinib (HS-10296) could also inhibit other EGFR sensitive mutations, including G719X, del19, L858R and L861Q.

Identifiers

SMILES: COC(C=C(N(C)CCN(C)C)C(NC(C=C)=O)=C1)=C1NC2=NC(C3=CN(C4CC4)C5=C3C=CC=C5)=CC=N2.[H]Cl
InChIKey: CUXBWKDZKQGJNN-UHFFFAOYSA-N

Specifications

MW (average): 562.1060
Formula: C₃₀H₃₆ClN₇O₂
CAS No.: 2134096-03-8
Physical state: Solid
Color: Off-white to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4°C, sealed storage, away from moisture; In solvent -20°C, 1 month;

Solubility

soluble in DMSO/H2O

Documents

References

[1]. Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76.

[2]. Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018 Feb 19;17(1):38.

[3]. Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. J Thorac Oncol. 2020;S1556-0

Same target

Search EGFR

Same research area

Search Cancer